UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 29, 2020

OR

TRANSITION REPORT PURSUANT TO SECTION 13

OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

COMMISSION FILE NUMBER 1-3619

----

PFIZER INC.

(Exact name of registrant as specified in its charter)

Delaware

13-5315170

(State of Incorporation)

(I.R.S. Employer Identification No.)

235 East 42nd Street, New York, New York 10017

(Address of principal executive offices) (zip code)

(212) 733-2323

(Registrant s telephone number)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $.05 par value

PFE

New York Stock Exchange

0.250% Notes due 2022

PFE22

New York Stock Exchange

1.000% Notes due 2027

PFE27

New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes

No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes

No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act:

Large Accelerated filer x Accelerated filer Non-accelerated filer Smaller reporting company Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes

No

At May 4, 2020, 5,554,833,754 shares of the issuer s voting common stock were outstanding.

Table of Contents

PART I. FINANCIAL INFORMATION

Page

Item 1.

Financial Statements

Condensed Consolidated Statements of Income for the three months ended March 29, 2020 and March 31, 2019

Condensed Consolidated Statements of Comprehensive Income for the three months ended March 29, 2020

and March 31, 2019

Condensed Consolidated Balance Sheets as of March 29, 2020 and December 31, 2019

Condensed Consolidated Statements of Equity for the three months ended March 29, 2020 and March 31, 2019

Condensed Consolidated Statements of Cash Flows for the three months ended March 29, 2020 and March 31, 2019

Notes to Condensed Consolidated Financial Statements

10

Review Report of Independent Registered Public Accounting Firm

42

Item 2.

Management s Discussion and Analysis of Financial Condition and Results of Operations

43

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

85

Item 4.

Controls and Procedures

85

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

86

Item 1A.

Risk Factors

86

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

88

Item 3.

Defaults Upon Senior Securities

88

Item 4.

Mine Safety Disclosures

88

Item 5.

Other Information

88

Item 6.

Exhibits

89

Signature

90

GLOSSARY OF DEFINED TERMS

Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Quarterly Report on Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. We also have used several other terms in this Quarterly Report on Form 10-Q, most of which are explained or defined below:

2019 Financial Report

Financial Report for the fiscal year ended December 31, 2019, which was filed as Exhibit 13 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2019

2019 Form 10-K

Annual Report on Form 10-K for the fiscal year ended December 31, 2019

ACA (Also referred to as U.S. Healthcare Legislation)

U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act

ACIP

Advisory Committee on Immunization Practices

ALK

anaplastic lymphoma kinase

Alliance revenues

Revenues from alliance agreements under which we co-promote products discovered or developed by other companies or us

Allogene

Allogene Therapeutics, Inc.

AML

Acute Myeloid Leukemia

Anacor

Anacor Pharmaceuticals, Inc.

Array

Array BioPharma Inc.

Astellas

Astellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.

Bamboo

Bamboo Therapeutics, Inc.

BioNTech

BioNTech SE

Biopharma

Pfizer Biopharmaceuticals Group

BMS

Bristol-Myers Squibb Company

CDC

U.S. Centers for Disease Control and Prevention

cGMP

current Good Manufacturing Practices

CHMP

Committee for Medicinal Products for Human Use

COVID-19

novel coronavirus disease of 2019

Developed Markets

U.S., Western Europe, Japan, Canada, South Korea, Australia, Scandinavian countries, Finland and

New Zealand

EMA

European Medicines Agency

Emerging Markets

Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea),

Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey

EPS

earnings per share

EU

European Union

Exchange Act

Securities Exchange Act of 1934, as amended

FASB

Financial Accounting Standards Board

FDA

U.S. Food and Drug Administration

GAAP

Generally Accepted Accounting Principles

GIST

gastrointestinal stromal tumors

GPD

Global Product Development organization

GSK

GlaxoSmithKline plc

hGH-CTP

human growth hormone

HIS

Hospira Infusion Systems

Hospira

Hospira, Inc.

HR+

hormone receptor-positive

IBT

Income before tax

ICU Medical

ICU Medical, Inc.

IPR&D

in-process research and development

IRS

U.S. Internal Revenue Service

IV

intravenous

Janssen

Janssen Biotech Inc.

J&J

Johnson & Johnson

JV

Joint Venture

King

King Pharmaceuticals LLC (formerly King Pharmaceuticals, Inc.)

LDL

low density lipoprotein

LIBOR

London Interbank Offered Rate

Lilly

Eli Lilly & Company

MCO

managed care organization

mCRC

metastatic colorectal cancer

MD&A

Management s Discussion and Analysis of Financial Condition and Results of Operations

Medivation

Medivation LLC (formerly Medivation, Inc.)

Meridian

Meridian Medical Technologies, Inc.

Moody s

Moody s Investors Service

Mylan

Mylan N.V.

NDA

new drug application

NSCLC

non-small cell lung cancer

OPKO

OPKO Health, Inc.

OTC

over-the-counter

PARP

poly ADP ribose polymerase

PBM

pharmacy benefit manager

Pharmacia

Pharmacia Corporation

PP&E

property, plant & equipment

PsA

psoriatic arthritis

Quarterly Report on Form 10-Q

Quarterly Report on Form 10-Q for the quarterly period ended March 29, 2020

RA

rheumatoid arthritis

RCC

renal cell carcinoma

R&D

research and development

Sandoz

Sandoz, Inc., a division of Novartis AG

SEC

U.S. Securities and Exchange Commission

SI&A

selling, informational and administrative

S&P

Standard and Poor s

TCJA

legislation commonly referred to as the U.S. Tax Cuts and Jobs Act of 2017

Therachon

Therachon Holding AG

UC

ulcerative colitis

U.K.

United Kingdom

U.S.

United States

ViiV

ViiV Healthcare Limited

VBP

Volume-based procurement program

WRDM

Worldwide Research, Development and Medical

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

Three Months Ended

(MILLIONS, EXCEPT PER COMMON SHARE DATA)

March 29,

2020

March 31,

2019

Revenues

12,028

13,118

Costs and expenses:

Cost of sales(a)

2,378

2,433

Selling, informational and administrative expenses(a)

2,873

3,339

Research and development expenses(a)

1,724

1,703

Amortization of intangible assets

885

1,183

Restructuring charges and certain acquisition-related costs

69

46

(Gain) on completion of Consumer Healthcare JV transaction

(6

Other (income)/deductions net

221

92

Income from continuing operations before provision for taxes on income

3,885

4,323

Provision for taxes on income

475

433

Income from continuing operations

3,410

3,889

Discontinued operations net of tax

Net income before allocation to noncontrolling interests

3,410

3,889

Less: Net income attributable to noncontrolling interests

Net income attributable to Pfizer Inc.

3,401

3,884

Earnings per common share basic:

Income from continuing operations attributable to Pfizer Inc. common shareholders

0.61

0.69

Discontinued operations net of tax

Net income attributable to Pfizer Inc. common shareholders

0.61

0.69

Earnings per common share diluted:

Income from continuing operations attributable to Pfizer Inc. common shareholders

0.61

0.68

Discontinued operations net of tax

Net income attributable to Pfizer Inc. common shareholders

0.61

0.68

Weighted-average shares basic

5,545

5,635

Weighted-average shares diluted

5,613

5,750

(a)

Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(UNAUDITED)

Three Months Ended

(MILLIONS OF DOLLARS)

March 29,

2020

March 31,

2019

Net income before allocation to noncontrolling interests

3,410

3,889

Foreign currency translation adjustments, net(a)

(1,272

324

Reclassification adjustments

(1,272

326

Unrealized holding gains/(losses) on derivative financial instruments, net

(501

267

Reclassification adjustments for (gains)/losses included in net income(b)

19

(263

(482

Unrealized holding gains/(losses) on available-for-sale securities, net

(51

40

Reclassification adjustments for losses included in net income(b)

15

11

(36

51

Benefit plans: actuarial losses, net

(166

Reclassification adjustments related to amortization

66

60

Reclassification adjustments related to settlements, net

53

Other

16

(23

(31

37

Reclassification adjustments related to amortization of prior service costs and other, net

(45

(46

Other

(1

(45

(46

Other comprehensive income/(loss), before tax

(1,867

372

Tax provision/(benefit) on other comprehensive income/(loss)

(377

25

Other comprehensive income/(loss) before allocation to noncontrolling interests

(1,490

348

Comprehensive income before allocation to noncontrolling interests

1,920

4,237

Less: Comprehensive income attributable to noncontrolling interests

Comprehensive income attributable to Pfizer Inc.

1,911

4,236

(a)

Amounts in the first quarter of 2020 include a loss of approximately $1.6 billion pre-tax ($1.2 billion after-tax) related to foreign currency translation adjustments attributable to our equity method investment in the GSK Consumer Healthcare joint venture (see Note 2B), partially offset by the results of our net investment hedging program.

(b)

Reclassified into Other (income)/deductions net and Cost of sales in the condensed consolidated statements of income. For additional information on amounts reclassified into Other (income)/deductions net and Cost of sales, see Note 7E. Financial Instruments: Derivative Financial Instruments and Hedging Activities.

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(MILLIONS OF DOLLARS)

March 29,

2020

December 31,

2019

(Unaudited)

Assets

Cash and cash equivalents

2,151

1,305

Short-term investments

8,199

8,525

Trade accounts receivable, less allowance for doubtful accounts: 2020 $527; 2019 $527

9,881

8,724

Inventories

8,423

8,283

Current tax assets

3,346

3,344

Other current assets

2,737

2,622

Total current assets

34,738

32,803

Equity-method investments

15,524

17,133

Long-term investments

2,696

3,014

Property, plant and equipment, less accumulated depreciation: 2020 $16,929; 2019 $16,789

14,040

13,967

Identifiable intangible assets, less accumulated amortization

34,464

35,370

Goodwill

58,502

58,653

Noncurrent deferred tax assets and other noncurrent tax assets

2,207

2,099

Other noncurrent assets

4,166

4,450

Total assets

166,336

167,489

Liabilities and Equity

Short-term borrowings, including current portion of long-term debt: 2020 $337; 2019 $1,462

16,007

16,195

Trade accounts payable

3,972

4,220

Dividends payable

2,104

Income taxes payable

1,150

980

Accrued compensation and related items

2,246

2,720

Other current liabilities

10,515

11,083

Total current liabilities

33,890

37,304

Long-term debt

36,281

35,955

Pension benefit obligations, net

5,442

5,638

Postretirement benefit obligations, net

1,093

1,124

Noncurrent deferred tax liabilities

5,268

5,578

Other taxes payable

12,212

12,126

Other noncurrent liabilities

6,812

6,317

Total liabilities

100,998

104,042

Commitments and Contingencies

Preferred stock

17

17

Common stock

470

468

Additional paid-in capital

87,680

87,428

Treasury stock

(111,010

(110,801

Retained earnings

101,000

97,670

Accumulated other comprehensive loss

(13,131

(11,640

Total Pfizer Inc. shareholders equity

65,026

63,143

Equity attributable to noncontrolling interests

312

303

Total equity

65,338

63,447

Total liabilities and equity

166,336

167,489

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY

(UNAUDITED)

PFIZER INC. SHAREHOLDERS

Preferred Stock

Common Stock

Treasury Stock

(MILLIONS, EXCEPT PREFERRED SHARES)

Shares

Stated Value

Shares

Par Value

Add l

Paid-In Capital

Shares

Cost

Retained Earnings

Accum. Other Comp.

Loss

Share-

holders Equity

Non-controlling interests

Total Equity

Balance, January 1, 2020

431

17

9,369

468

87,428

(3,835

(110,801

97,670

(11,640

63,143

303

63,447

Net income

3,401

3,401

3,410

Other comprehensive income/(loss), net of tax

(1,490

(1,490

(1,490

Cash dividends declared:

Common stock

(71

(71

(71

Preferred stock

Noncontrolling interests

Share-based payment transactions

23

252

(6

(209

44

44

Purchases of common stock

Preferred stock conversions and redemptions

(14

(1

(1

(1

(1

Other

Balance, March 29, 2020

417

17

9,393

470

87,680

(3,841

(111,010

101,000

(13,131

65,026

312

65,338

PFIZER INC. SHAREHOLDERS

Preferred Stock

Common Stock

Treasury Stock

(MILLIONS, EXCEPT PREFERRED SHARES)

Shares

Stated Value

Shares

Par Value

Add l

Paid-In Capital

Shares

Cost

Retained Earnings

Accum. Other Comp.

Loss

Share-

holders Equity

Non-controlling interests

Total Equity

Balance, January 1, 2019

478

19

9,332

467

86,253

(3,615

(101,610

89,554

(11,275

63,407

351

63,758

Net income

3,884

3,884

3,889

Other comprehensive income/(loss), net of tax

353

353

(4

348

Cash dividends declared:

Common stock

(68

(68

(68

Preferred stock

Noncontrolling interests

Share-based payment transactions

26

383

(7

(306

78

78

Purchases of common stock

(180

(8,865

(8,865

(8,865

Preferred stock conversions and redemptions

(12

(1

(1

(1

Other(a)

19

19

19

Balance, March 31, 2019

466

19

9,358

468

86,635

(3,801

(110,781

93,388

(10,923

58,806

352

59,158

(a)

The increase to Retained earnings represents the cumulative effect of the adoption of a new accounting standard in the first quarter of 2019 for leases. For additional information, see Notes to Consolidated Financial Statements Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2019 in our 2019 Financial Report.

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Three Months Ended

(MILLIONS OF DOLLARS)

March 29,

2020

March 31,

2019

Operating Activities

Net income before allocation to noncontrolling interests

3,410

3,889

Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:

Depreciation and amortization

1,218

1,545

Asset write-offs and impairments

45

155

TCJA impact(a)

(131

Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed

(6

Deferred taxes from continuing operations

109

(60

Share-based compensation expense

64

185

Benefit plan contributions in excess of expense/income

(248

(151

Other adjustments, net

123

(236

Other changes in assets and liabilities, net of acquisitions and divestitures

(1,581

(3,498

Net cash provided by operating activities

3,133

1,698

Investing Activities

Purchases of property, plant and equipment

(463

(460

Purchases of short-term investments

(2,551

(1,402

Proceeds from redemptions/sales of short-term investments

3,257

3,601

Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less

(416

5,941

Purchases of long-term investments

(22

(84

Proceeds from redemptions/sales of long-term investments

152

44

Acquisitions of intangible assets

(32

(158

Other investing activities, net

67

Net cash provided by/(used in) investing activities

(71

7,550

Financing Activities

Proceeds from short-term borrowings

5,302

609

Principal payments on short-term borrowings

(7,551

(1,766

Net proceeds from short-term borrowings with original maturities of three months or less

3,207

2,032

Proceeds from issuance of long-term debt

1,241

4,942

Principal payments on long-term debt

(2,181

(3,004

Purchases of common stock

(8,865

Cash dividends paid

(2,105

(2,045

Proceeds from exercise of stock options

124

126

Other financing activities, net